Illumina, Inc. (LON:0J8Z)

Market Cap	11.80B
Revenue (ttm)	3.47B
Net Income (ttm)	-971.37M
Shares Out	n/a
EPS (ttm)	-6.11
PE Ratio	n/a
Forward PE	n/a
Dividend	2.45 (2.61%)
Ex-Dividend Date	n/a

Volume	6,024
Average Volume	3,854
Open	97.13
Previous Close	97.36
Day's Range	93.97 - 98.81
52-Week Range	89.21 - 232.20
Beta	1.10
RSI	19.91
Earnings Date	Feb 7, 2025

About Illumina

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 9,030
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J8Z

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial numbers in USD